Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02018861
Title A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Incyte Corporation
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Alabama At Birmingham Comprehensive Cancer Center Birmingham Alabama 35205 United States Details
University of Michigan Cancer Center Ann Arbor Michigan 48109 United States Details
Karmanos Cancer Institute Detroit Michigan 48201 United States Details
Nyu Langone Laura and Isaac Perlmutter Cancer Center New York New York 10016 United States Details
University Hospitals Case Medical Center Cleveland Ohio 44106 United States Details
Greenville Health System Cancer Institute Greenville South Carolina 29605 United States Details
Baylor Charles A. Sammons Cancer Center Dallas Texas 75246 United States Details
*Shaded cells indicate that there was no data available from for the field